Nasus Pharma Ltd. received a No-Objection Letter from Health Canada for a Phase 2 clinical study of NS002, an intranasal epinephrine powder formulation for anaphylaxis. This milestone allows Nasus to move forward with the trial. CEO Dan Teleman believes this approval is crucial in revolutionizing anaphylaxis treatment, offering a needle-free option with Nasus’s Nasax® technology. Nasus Pharma focuses on developing intranasal powder products for acute medical conditions. The company’s PBI technology aims for rapid and reliable drug delivery. For more information, visit Nasus Pharma’s website or follow them on social media.

Read more at GlobeNewswire: Nasus Pharma Announces Approval from Health Canada to